Apple Turns 50: From Garage Startup to AI Crossroads 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
 and Lead Plaintiff Deadline: March 13, 2017 - EconoTimes)
NEW YORK, Jan. 16, 2017 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo" or the "Company") (NYSE:NVO) and certain of its officers, and is on behalf of a class consisting of all persons or entities who purchased Novo American Depositary Receipts ("ADR") between April 30, 2015 and October 27, 2016, both dates inclusive (the “Class Period”). Investors with losses in excess of $1 million are advised to join this case by visiting the firm’s site: http://www.bgandg.com/nvo.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint alleges that throughout the Class Period, Novo reported materially false and misleading Company earnings and predications in that they were inflated through the collusive price fixing of Novo’s insulin drugs. The Complaint also alleges that Novo misrepresented and concealed the true extent of the pricing pressures it was experiencing from pharmacy benefit managers.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/nvo or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. Investors with losses in excess of $1 million in Novo have until March 13, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]
